Indicated in cases of non-inflammatory joint degenerative disease such as osteoarthritis and avascular necrosis. Rheumatoid arthritis. Correction of functional deformity. Fractures of the proximal humerus. Clinical control problems difficult to administer that includes fist arthropathy.
“The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.